Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 15 versus DEXMETHYLPHENIDATE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 15 versus DEXMETHYLPHENIDATE HYDROCHLORIDE.
ADDERALL XR 15 vs DEXMETHYLPHENIDATE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.
Dexmethylphenidate is a central nervous system (CNS) stimulant. Its mechanism of action in ADHD is not fully understood, but it is believed to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.
Initial: 5 mg orally twice daily (morning and noon) with or without food; titrate in increments of 5 mg weekly; maximum 20 mg twice daily (40 mg/day).
None Documented
None Documented
The terminal elimination half-life of amphetamine in adults is approximately 10-13 hours; in children, it is slightly shorter (6-8 hours). For the l-amphetamine isomer, the half-life is 9-11 hours. The extended-release formulation provides a prolonged duration of effect due to a biphasic release profile.
2-4 hours (immediate-release); 4-5 hours (extended-release); clinical context: short half-life necessitates multiple daily dosing for immediate-release formulations
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites including deaminated and oxidized products; fecal excretion accounts for less than 10%.
Renal (78-97% as metabolites and unchanged drug, with approximately 50% as de-esterified metabolites and 30% as unchanged drug)
Category C
Category A/B
CNS Stimulant
CNS Stimulant